Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) has issued an update.
ResMed Inc. has reported updated figures for its CHESS Depositary Interests (CDIs) on issue for February 2026, showing 574,157,700 CDIs on issue at month-end, down from 580,546,240 the previous month, driven by net transfers between CDIs quoted on the ASX and common stock traded on the NYSE. The company also disclosed modest reductions in underlying securities over which CDIs have not been issued, reflecting a combination of transfers between ASX CDIs and NYSE common stock, issuance of new shares tied to employee equity plans, and ongoing share repurchases on the NYSE, underscoring active capital management and cross-market share movements.
The most recent analyst rating on (AU:RMD) stock is a Hold with a A$39.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. is a medical device and digital health company focused on sleep and respiratory care, best known for its devices and software used to diagnose, treat, and manage sleep apnea and other chronic respiratory conditions. The company is dual-listed, with common stock traded on the NYSE and CHESS Depositary Interests (CDIs) quoted on the ASX under the code RMD, allowing Australian investors exposure to its U.S.-listed shares.
Average Trading Volume: 1,113,865
Technical Sentiment Signal: Hold
Current Market Cap: A$53.37B
For detailed information about RMD stock, go to TipRanks’ Stock Analysis page.